TRANSMEDICS GROUP INC
TMDXNASDAQTrading Snapshot
- Day Range
- $66.15 – $68.96
- 52-Week Range
- $60.11 – $156.00
- Volume (shares)
- 390,190.714
- Avg Volume (shares)
- —
- Shares Outstanding
- 34.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $605M
- Last Q Revenue
- $190M
- P/E Ratio
- 15.3
- P/S Ratio
- 3.5x
- EPS (TTM)
- $3.73
- Dividend Yield
- —
- Dilution (1yr)
- +16.2%
TRANSMEDICS GROUP INC
TMDX
StockOtter · stockotter.spaceAbout TRANSMEDICS GROUP INC
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
TransMedics selects Gogo Galileo HDX for nationwide organ transport fleet
Reliable, high-performance connectivity will support time-critical transport and monitoring of donor organs for transplants aboard 22 Embraer Phenom 300E aircraft Reliable, high-performance connectivity will support time
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and
A Look at TransMedics Group Inc (TMDX) After 3.1% Decline -- GF Value $160.75 vs Price $72.40
On October 21, 2026, TransMedics Group Inc (TMDX) shares fell by 3.1%, bringing the current price to $72.40. This decline is notable within a 52-week range of $
Critical Review: TransMedics Group (NASDAQ:TMDX) & iRhythm Technologies (NASDAQ:IRTC)
TransMedics Group (NASDAQ: TMDX - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells Investors
On October 01, 2026, TransMedics Group Inc (TMDX) shares fell 5.8%, closing at $78.64. The stock's performance over the past year has been challenging, with a 5
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to contact the